A Study of Oral Contraception Under Simulated OTC Conditions

PHASE3TerminatedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

September 9, 2018

Study Completion Date

November 14, 2018

Conditions
Contraception
Interventions
DRUG

Norgestrel 0.075 mg tablets

"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."

Trial Locations (44)

18015

HRA Pharma Investigational site, Bethlehem

21228

HRA Pharma Investigational site, Catonsville

23192

HRA Pharma Investigational site, Montpelier

27215

HRA Pharma Investigational site, Burlington

30224

HRA Pharma Investigational site, Griffin

30721

HRA Pharma Investigational site, Dalton

33578

HRA Pharma Investigational site, Riverview

35111

HRA Pharma Investigational site, McCalla

35209

HRA Pharma Investigational site, Homewood

35215

HRA Pharma Investigational site, Birmingham

37043

HRA Pharma Investigational site, Clarksville

37311

HRA Pharma Investigational site, Cleveland

45368

HRA Pharma Investigational Site, South Charleston

54001

HRA Pharma Investigational site, Amery

55070

HRA Pharma Investigational Site, Saint Francis

55303

HRA Pharma Investigational site, Anoka

55330

HRA Pharma Investigational site, Elk River

55432

HRA Pharma Investigational site, Fridley

61121

HRA Pharma Investigational site, Hartford

63088

HRA Pharma Investigational site, Manchester

63343

HRA Pharma Investigational site, Elsberry

64485

HRA Pharma Investigational Site, Savannah

65111

HRA Pharma Investigational site, New Haven

65807

HRA Pharma Investigational site, Springfield

75092

HRA Pharma Investigational site, Sherman

77008

HRA Pharma Investigational site, Houston

77099

HRA Pharma Investigational site, Houston

84010

HRA Investigational site, Bountiful

84075

HRA Pharma Investigational site, Syracuse

84664

HRA Pharma Investigational site, Mapleton

85704

HRA Pharma Investigational site, Tucson

87104

HRA Pharma Investigational site, Albuquerque

87109

HRA Pharma Investigational site, Albuquerque

87110

HRA Pharma Investigational site, Albuquerque

90005

HRA Pharma Investigational site, Los Angeles

90241

HRA Pharma Investigational site, Downey

90631

HRA Pharma Investigational site, La Habra

90806

HRA Pharma Investigational site, Long Beach

98022

HRA Pharma Investigational site, Enumclaw

98028

HRA Pharma Investigational site, Kenmore

98117

HRA Pharma Investigational site, Seattle

98290

HRA Pharma Investigational site, Snohomish

06606

HRA Pharma Investigational site, Bridgeport

08831

HRA Pharma Investigational site, Monroe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HRA Pharma

INDUSTRY

NCT03559010 - A Study of Oral Contraception Under Simulated OTC Conditions | Biotech Hunter | Biotech Hunter